Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Investig Drugs. 2004 Apr;5(4):430-5.

Rimonabant Sanofi-Synthélabo.

Author information

  • 1University of Alabama at Birmingham, Department of Nutrition Sciences, Ryals Public Health Building, 1665 University Blvd, Birmingham, AL 35294-0022, USA.

Abstract

Rimonabant, an antagonist of central cannabinoid type 1 (CB1) receptors, is being developed by Sanofi-Synthélabo for the potential treatment of obesity and as a potential smoking cessation agent. Phase III trials were initiated for obesity in August 2001 and were ongoing in September 2003. By September 2002, the compound had entered phase III trials for smoking cessation, and these trials were ongoing in September 2003.

PMID:
15134285
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk